CA2303791C - Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity - Google Patents
Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity Download PDFInfo
- Publication number
- CA2303791C CA2303791C CA2303791A CA2303791A CA2303791C CA 2303791 C CA2303791 C CA 2303791C CA 2303791 A CA2303791 A CA 2303791A CA 2303791 A CA2303791 A CA 2303791A CA 2303791 C CA2303791 C CA 2303791C
- Authority
- CA
- Canada
- Prior art keywords
- magnetic
- poles
- pole
- vertex
- focusing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title abstract description 304
- 230000006641 stabilisation Effects 0.000 title abstract description 4
- 238000011105 stabilization Methods 0.000 title abstract description 4
- 230000004907 flux Effects 0.000 claims abstract description 233
- 238000010304 firing Methods 0.000 claims abstract description 48
- 230000036982 action potential Effects 0.000 claims abstract description 18
- 208000002193 Pain Diseases 0.000 claims description 110
- 230000036407 pain Effects 0.000 claims description 95
- 210000002569 neuron Anatomy 0.000 claims description 52
- 230000005012 migration Effects 0.000 claims description 51
- 238000013508 migration Methods 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 40
- 210000000056 organ Anatomy 0.000 claims description 30
- 210000003128 head Anatomy 0.000 claims description 28
- 210000004556 brain Anatomy 0.000 claims description 18
- 239000000835 fiber Substances 0.000 claims description 17
- 210000005036 nerve Anatomy 0.000 claims description 12
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 11
- 206010003402 Arthropod sting Diseases 0.000 claims description 10
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 108090000312 Calcium Channels Proteins 0.000 claims description 7
- 102000003922 Calcium Channels Human genes 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 210000004227 basal ganglia Anatomy 0.000 claims description 7
- 210000000929 nociceptor Anatomy 0.000 claims description 6
- 108091008700 nociceptors Proteins 0.000 claims description 6
- 241000050051 Chelone glabra Species 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 2
- 210000001213 vestibule labyrinth Anatomy 0.000 claims description 2
- 210000000707 wrist Anatomy 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000001473 noxious effect Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000003068 static effect Effects 0.000 abstract description 209
- 238000011282 treatment Methods 0.000 abstract description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 208000035475 disorder Diseases 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 17
- 210000001044 sensory neuron Anatomy 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 description 122
- 241001465754 Metazoa Species 0.000 description 89
- 230000008569 process Effects 0.000 description 43
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 35
- 230000035876 healing Effects 0.000 description 34
- 206010030113 Oedema Diseases 0.000 description 29
- 208000027418 Wounds and injury Diseases 0.000 description 24
- 230000004224 protection Effects 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 230000030833 cell death Effects 0.000 description 23
- 230000008961 swelling Effects 0.000 description 21
- 206010010904 Convulsion Diseases 0.000 description 19
- 208000014674 injury Diseases 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 238000001356 surgical procedure Methods 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 14
- 230000004064 dysfunction Effects 0.000 description 13
- 230000002269 spontaneous effect Effects 0.000 description 13
- 208000000094 Chronic Pain Diseases 0.000 description 12
- 102000002322 Egg Proteins Human genes 0.000 description 12
- 108010000912 Egg Proteins Proteins 0.000 description 12
- 208000006011 Stroke Diseases 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 210000004681 ovum Anatomy 0.000 description 12
- 208000016285 Movement disease Diseases 0.000 description 11
- 206010047700 Vomiting Diseases 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 11
- 230000003389 potentiating effect Effects 0.000 description 11
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 10
- 238000012790 confirmation Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 208000028867 ischemia Diseases 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 210000000273 spinal nerve root Anatomy 0.000 description 10
- 206010021143 Hypoxia Diseases 0.000 description 9
- 230000004720 fertilization Effects 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 230000002459 sustained effect Effects 0.000 description 9
- 208000035154 Hyperesthesia Diseases 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 206010002383 Angina Pectoris Diseases 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 7
- 238000005299 abrasion Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- 208000034656 Contusions Diseases 0.000 description 6
- 206010033425 Pain in extremity Diseases 0.000 description 6
- 206010059604 Radicular pain Diseases 0.000 description 6
- 230000006022 acute inflammation Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000009519 contusion Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000007257 malfunction Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000008058 pain sensation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 208000007056 sickle cell anemia Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- 206010061224 Limb discomfort Diseases 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 229960002504 capsaicin Drugs 0.000 description 5
- 235000017663 capsaicin Nutrition 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- 238000002692 epidural anesthesia Methods 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108010052164 Sodium Channels Proteins 0.000 description 4
- 102000018674 Sodium Channels Human genes 0.000 description 4
- 230000009692 acute damage Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 229940064790 dilantin Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 3
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002497 edematous effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229910000497 Amalgam Inorganic materials 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 229910001335 Galvanized steel Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000008397 galvanized steel Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 210000005061 intracellular organelle Anatomy 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 201000003152 motion sickness Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000004636 vulcanized rubber Substances 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000009516 brain contusion Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- OORLZFUTLGXMEF-UHFFFAOYSA-N sulfentrazone Chemical compound O=C1N(C(F)F)C(C)=NN1C1=CC(NS(C)(=O)=O)=C(Cl)C=C1Cl OORLZFUTLGXMEF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002455 vasospastic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/06—Magnetotherapy using magnetic fields produced by permanent magnets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Magnetic Treatment Devices (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92663397A | 1997-09-10 | 1997-09-10 | |
| US08/926,633 | 1997-09-10 | ||
| PCT/US1998/018967 WO1999012605A2 (en) | 1997-09-10 | 1998-09-10 | Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2303791A1 CA2303791A1 (en) | 1999-03-18 |
| CA2303791C true CA2303791C (en) | 2013-01-15 |
Family
ID=25453486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2303791A Expired - Lifetime CA2303791C (en) | 1997-09-10 | 1998-09-10 | Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1030712B1 (enExample) |
| JP (1) | JP2003533233A (enExample) |
| KR (1) | KR100672787B1 (enExample) |
| CN (1) | CN1214828C (enExample) |
| AT (1) | ATE419894T1 (enExample) |
| AU (1) | AU755495B2 (enExample) |
| BR (1) | BR9812083A (enExample) |
| CA (1) | CA2303791C (enExample) |
| DE (1) | DE69840452D1 (enExample) |
| IL (2) | IL134976A0 (enExample) |
| MX (1) | MXPA00002499A (enExample) |
| NZ (2) | NZ534779A (enExample) |
| WO (1) | WO1999012605A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608035B2 (en) | 1996-09-10 | 2009-10-27 | Gradient Technologies, Llc | Method and morphologically adaptable apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity |
| US6461288B1 (en) | 1996-09-10 | 2002-10-08 | Holcomb Healthcare Services | Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity |
| US7876546B2 (en) | 2006-09-19 | 2011-01-25 | Kci Licensing Inc. | Component module for a reduced pressure treatment system |
| CZ306539B6 (cs) * | 2015-07-06 | 2017-03-01 | Tesla Medical, S.R.O. | Elektrostimulační zařízení |
| CA2991674C (en) | 2015-07-06 | 2023-05-23 | Tesla Medical, S.R.O. | Electrostimulation device |
| CZ306538B6 (cs) * | 2015-07-06 | 2017-03-01 | Tesla Medical, S.R.O. | Elektrostimulační zařízení |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2301010C2 (de) | 1973-01-10 | 1985-08-01 | Takeo Tokio/Tokyo Nakayama | Medizinische Behandlungsvorrichtung mit mehreren nebeneinander angeordneten Dauermagneten |
| US4105017A (en) | 1976-11-17 | 1978-08-08 | Electro-Biology, Inc. | Modification of the growth repair and maintenance behavior of living tissue and cells by a specific and selective change in electrical environment |
| DE8128911U1 (de) | 1981-10-02 | 1982-06-16 | Energy-Pak Europe Ltd., 9490 Vaduz | Magnetpflaster |
| US5312321A (en) | 1986-11-21 | 1994-05-17 | Holcomb Technology, Inc. | Method and apparatus for suppressing neuron action potential firings |
| EP0428474A3 (en) * | 1989-11-13 | 1992-04-29 | Holcomb Medical Corporation | Therapeutic magnetic shoe and method of application |
| CA2258854C (en) * | 1995-06-19 | 2007-11-20 | Robert R. Holcomb | Electromagnetic therapeutic treatment device and methods of using same |
| WO1997004830A1 (en) * | 1995-07-28 | 1997-02-13 | Gray James R | Use of a polarizing field to modify the efficacy of a bioactive agent |
-
1998
- 1998-09-10 CA CA2303791A patent/CA2303791C/en not_active Expired - Lifetime
- 1998-09-10 NZ NZ534779A patent/NZ534779A/en unknown
- 1998-09-10 NZ NZ551988A patent/NZ551988A/en not_active IP Right Cessation
- 1998-09-10 IL IL13497698A patent/IL134976A0/xx not_active IP Right Cessation
- 1998-09-10 WO PCT/US1998/018967 patent/WO1999012605A2/en not_active Ceased
- 1998-09-10 BR BR9812083-2A patent/BR9812083A/pt not_active Application Discontinuation
- 1998-09-10 KR KR1020007002587A patent/KR100672787B1/ko not_active Expired - Fee Related
- 1998-09-10 CN CNB988109948A patent/CN1214828C/zh not_active Expired - Fee Related
- 1998-09-10 DE DE69840452T patent/DE69840452D1/de not_active Expired - Fee Related
- 1998-09-10 AT AT98948157T patent/ATE419894T1/de not_active IP Right Cessation
- 1998-09-10 JP JP2000510498A patent/JP2003533233A/ja not_active Ceased
- 1998-09-10 EP EP98948157A patent/EP1030712B1/en not_active Expired - Lifetime
- 1998-09-10 MX MXPA00002499A patent/MXPA00002499A/es active IP Right Grant
- 1998-09-10 AU AU94788/98A patent/AU755495B2/en not_active Expired
-
2000
- 2000-03-09 IL IL134976A patent/IL134976A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999012605A8 (en) | 1999-04-22 |
| AU755495B2 (en) | 2002-12-12 |
| NZ534779A (enExample) | 2007-05-31 |
| CA2303791A1 (en) | 1999-03-18 |
| CN1278742A (zh) | 2001-01-03 |
| JP2003533233A (ja) | 2003-11-11 |
| ATE419894T1 (de) | 2009-01-15 |
| AU9478898A (en) | 1999-03-29 |
| KR20010052066A (ko) | 2001-06-25 |
| DE69840452D1 (de) | 2009-02-26 |
| EP1030712A4 (en) | 2006-09-13 |
| EP1030712A1 (en) | 2000-08-30 |
| BR9812083A (pt) | 2002-01-15 |
| MXPA00002499A (es) | 2004-09-10 |
| EP1030712B1 (en) | 2009-01-07 |
| NZ551988A (en) | 2008-09-26 |
| IL134976A (en) | 2006-06-11 |
| IL134976A0 (en) | 2001-05-20 |
| WO1999012605A2 (en) | 1999-03-18 |
| CN1214828C (zh) | 2005-08-17 |
| KR100672787B1 (ko) | 2007-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8585569B2 (en) | Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity | |
| US9764154B2 (en) | Method and morphologically adaptable apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity | |
| US9415233B2 (en) | Apparatus and method for electromagnetic treatment of neurological pain | |
| US9433797B2 (en) | Apparatus and method for electromagnetic treatment of neurodegenerative conditions | |
| US10426967B2 (en) | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke | |
| US5752911A (en) | Electromagnetic method of treatment of epilepsy and apparatus | |
| Solomon et al. | Safety and effectiveness of cranial electrotherapy in the treatment of tension headache | |
| CA2303791C (en) | Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity | |
| Inamdar et al. | A review on transcutaneous electrical nerve stimulation and its applications | |
| WO2019239233A1 (es) | Equipo y metodo generador, concentrador y direccionador de campos electromagnéticos para regeneración celular | |
| EP0930915B1 (en) | Electromagnetic therapeutic treatment device | |
| RU58043U1 (ru) | Устройство для магнитотерапии | |
| Arnold | The evolution of bioelectronic medicine | |
| Lambert et al. | Microcurrent therapy and the treatment of soft tissue injury | |
| Naydenov et al. | INFLUENCE OF THE MAGNETIC FIELD ON THE LIVING ORGANISMS AND HUMANS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180910 |